CheckMyRecalls

Bristol-Myers Squibb Company recalls Opdualag (nivolumab and…

Bristol-Myers Squibb Company recalls Opdualag (nivolumab and relatlimab-rmbw) injection

Published
29 Oct 2025
Units affected
12,778 total vials
Agency
FDA
Country
United States

The hazard

Lack of Assurance of Sterility.

Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.

What to do

Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.

  • Check the lot number on the box or bottle.
  • Talk to your pharmacist or doctor before stopping any prescribed medicine.
  • Return the product to the pharmacy for safe disposal.
Read the official FDA notice

Product details

Opdualag (nivolumab and relatlimab-rmbw) injection, 240 mg and 80 mg/20 mL (12mg and 4mg/mL),Single Dose Vial, RX Only, Bristol-Myers Squibb Company, Princeton, NJ 08543, NDC 0003-7125-11

Brand / company
Bristol-Myers Squibb Company
Codes / lots
Lot: 033A23B, Expiry: 4/30/2026
Distribution
Nationwide in the USA
Recall status
Ongoing

Source: U.S. Food and Drug Administration, published 29 Oct 2025. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.